Psychometric assessment of the Injection Pen Assessment Questionnaire (IPAQ): measuring ease of use and preference with injection pens for human growth hormone.

Plain-language guide to PMID 23046797 (2012): open-label and multicenter phase 3 clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 23046797
Journal: Health and quality of life outcomes
Year: 2012
Study type: Clinical Trial, Phase III
Authors: Pleil AM et al. (5 authors)
DOI: 10.1186/1477-7525-10-126

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this phase 3 clinical trial publication.

To examine the psychometric properties of the Injection Pen Assessment Questionnaire (IPAQ) including the following: 1) item and scale characteristics (e.g., frequencies, item distributions, and factor structure), 2) reliability, and 3) validity.

Who Took Part

PubMed tags the participants as both men and women.

Focus groups and one-on-one dyad interviews guided the development of the IPAQ.

The IPAQ was subsequently tested in 136 parent-child dyads in a Phase 3, 2-month, open-label, multicenter trial for a new Genotropin(®) disposable pen.

How the Study Was Run

The design is described as open-label and multicenter.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.

More than one site took part, so the participants came from several places.

Factor analysis was performed to inform the development of a scoring algorithm, and reliability and validity of the IPAQ were evaluated using the data from this two months study.

Psychometric analyses were conducted separately for each injection pen.

What Was Measured

PubMed files the paper under topics including Factor Analysis, Statistical, Growth Disorders, Human Growth Hormone, Injections, Jet, Needles, Patient Preference and Psychometrics.

What This Means in Plain Language

The paper is an open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (Health and quality of life outcomes), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.